Assessment of Peri-procedural Myocardial Injury in Patients of Post-percutaneous Coronary Intervention: Diagnosis through Serum Biomarkers as Cardiac Troponin T and Creatine Kinase Myocardial Isoform
DOI:
https://doi.org/10.21276/wn8stz83Keywords:
Biochemical biomarkers, Percutaneous coronary intervention, Risk of myocardial damage, Serum troponin MACEAbstract
Background: Cardiac troponin (CTnT) and creatinine kinase myocardial isoform (CKMB) are suitable marker for myocardial injury following percutaneous coronary intervention (PCI). Elevation of these markers lead to major adverse cardiac events (MACEs). The objective was to detect the elevation of serum CTnT and CKMB during post-PCI period and identify MACE during six-month followed up among patients in eastern Indian. Methods: In present study, 100 patients were randomly selected for coronary angioplasty between April2012 to March2013. All the cases were referred to catheterization laboratory for elective PCI for single vessel or multivessel in native coronary artery. The CTnT and CKMB parameters were estimated as per standard protocol. The categorization was done on the basis of baseline (normal value), ≤3time and >3time elevation for both the biomarkers and respective MACEs as MACE-1, MACE-2, MACE-3, MACE-4 and MACE-5 were determined. Results: There were more MACE in patients in six month follow up who sustainned >3times elevation in CTnT and CKMB during pos-PCI period. There was highly significant correlation (P<0.001 and P<0.01) with increasing trend of CTnT and CKMB elevation and risk of MACEs. MACEs were significantly (P<0.001 and P<0.01) correlated with diabetes mellitus, hypertension, renal dysfunction, fluoroscopy time, stent length, left ventricular ejection fraction and type of lesion. It was also observed that more hospital stay led to elevation of CTnT and CKMB. Conclusions: It is concluded that the elevation of CTnT and CKMB in serum during post-PCI can predict MACEs in six-month follow up in stable ischaemic heart disease.
Downloads
References
Roberts R, Sobel BE. Editorial: Isoenzymes of creatine phosphokinase and diagnosis of myocardial infarction. Ann. Intern. Med. 1973;79(5):741-743.
Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mid transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536.
Gerhardt W, Nordin G, Ljungdahl L. Can troponin T replace CK MBmass as “gold standard” for acute myocardial infarction (“AMI”)? Scand. J. Clin. Lab. Invest. Suppl. 1999;230:83-89.
Desmet W, Dens J, Coussement P, Van de Werf. Does adenosine prevent myocardial micronecrosis following percuatenous coronary interventions? The ADELINE pilot trial. Heart. 2002;88:293-295.
Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A, et al. Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta blocker. Circulation. 2003;107:2914-2919.
Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J. Am. Coll. Cardiol. 2006;48(1):1-11.
Morrow DA, Cannon CP, Jesse RL, Newby K, Ravkilde J, Storrow AB, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin. Chem. 2007;53(4):552-574.
Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc. Health Risk Manag. 2010;6: 691-699.
Richardi MJ, Wu E, Davidson CJ, Chor KM, Klocke FJ, Bonow RO, et al. Visualization of discrete microinfarction after percuatenous coronary intervention associated with mild creatine kinase-MB elevation. Circulation. 2001;103:2780-2783.
Selvanayagam JB, Porto I, Channon K, Peterson SE, Francis JM, Neubauer S, et al. Troponin elevation after percuatenous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation.2005;111:1027-1032.
Alpert JS, Thygesen K. Myocardial infarction redefined. A consensus document of joint Europian society of cardiology/American college of Cardiology Committee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 2000;36:959-969.
Braunwald E. Unstable angina: a classification. Circulation. 1989;80:410-414.
Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB, McCallister BD, et al. Guidelines for percutaneous transluminal coronary angioplasty, a report of the ACC/AHA task force on assessment of diagnostic and therapeutic cardiovascular procedures. J. Am. Coll. Cardiol. 1993;22:2033-2204.
Balian V, Galli M, Repetto S, Luvini M, Galdangelo F, Castiglioni B, et al. Intracoronary ST segment shift soon after elective percutaneous coronary intervention accurately predicts periprocedural myocardial injury. Circulation. 2006;114:1948-1954.
Varani E, Balducelli M, Vecchi G, Gatti C, Ricci Lucchi G, Maresta A. Occurrence of non-Q wave myocardial infarction following percuatenous coronary intervention in the stent era: systemic monitoring of the three markers of myocardial necrosis. J. Interven. Cardiol. 2005;18:243-248.
Cavallini C, Savonitto S, Violini S, Arraiz G, Plebani M, Olivari Z, et al. Impact of the elevation of biochemical markers of myocardial damage on long term mortality after percuatenous coronary intervention: result of the CK-MB and PCI study. Eur. Heart J. 2005;26:1494-1498
Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, et al. Creatinine kinase MB elevation after percuatenous intervention predicts adverse outcome in patients with acute coronary syndromes. Eur. Heart J. 2004;25:313-321.
Kini AS, Lee P, Marmur JD, Agarwal A, Duffy ME, Kim MC, et al. Correlation of postpercutaneous coronary intervention creatine kinase MB and troponin I elevation on predicting mid term mortality. Am. J. Cardiol. 2004;93:18-23.
Ioannidis JPA, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase – MB isoenzyme after percuatenous coronary intervention. J. Am. Coll. Cardiol. 2003;42:1406-1411.
Fuchs S, Kornowski, Mehran R, Lansky AJ, Satler LF, Pichard AD, et al. Prognostic value of cardiac troponin I levels following catheter based coronary interventions. Am. J. Cardiol. 2000;85:1077-1082.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966;50:163-170.
Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin. Chem. 2010;56(4):642-650.
Mair J, Artner-Dworzak E, Dienstl A, Lechleitner P, Morass B, Smidt J, et al. Early detection of acute myocardial infarction by measurement of mass concentration of creatine kinase-MB. Am. J. Cardiol. 1991;68:1545-1550.
Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842.
Tate JR. Troponin revisited 2008: assay performance. Clin. Chem. Lab. Med. 2008;46(11):1489-1500.
Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Allan S. Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin. Chem. 2010;56:254-261.
Horder M., Elser RC, Gerhardt W, Mathieu M, Sampson EJ. Approved Recommendation of IFCC Methods for the Measurement of Catalytic Concentration of Enzymes, Part 7 IFCC Method for Creatine Kinase. Eur. J. Clin. Chem. Clin. Biochem. 1991;29:435-456.
Stein W. Laboratory diagnosis of acute myocardial infarction using CK and CK-MB by inmmunoinhibition. Darmstadt: GIT Verlag, 1988;20-7.
Cavallini C, Savonitto S, Violini R, Arraiz G, Plebani M, Olivari Z, et al. on behalf of the Italian ‘Atherosclerosis, Thrombosis, and Vascular Biology’ and ‘Society for Invasive Cardiology-GISE’ Investigators. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur. Heart J. 2005;26:1494-1498.
Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J. Am. Coll. Cardiol. 2006;4:1765-1770.
Balian V, Galli M, Repetto S, Luvini M, Galdangelo F, Castiglioni B, et al. Intracoronary ST segment shift soon after elective percutaneous coronary intervention accurately predicts periprocedural myocardial injury. Circulation. 2006;114:1948-1954.
ESPRIT Investigators Enhanced suppression of platelet IIb/IIIa receptor with Integrelin Therapy; novel dosing regimen of Eptifibatide in planned coronary stent implantation (ESPRIT) a randomized placebo controlled trial. Lancet. 2000;356: 2037-2044.
Lim CCS, van Gaal WJ, Testa L, Cuculi F, Arnold JR, Karamitsos T, et al. With the “universal definition” measurement of creatine kinase myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J. Am. Coll. Cardiol. 2011;57:653-661.
Kozucu M. Lack of ST segment depression normalization after PCI is a predictor of 5 year mortality is patients with ST elevation myocardial infarction. Circulation. 2007;71:1851-1856.
Zhang M, He H, Wang Z-M, Xu Z, Zhou N, Tao Z, et al. Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center
and double-blind study. J. Biomed. Res. 2014; 28(2):98-107.
Luo L, Zhao S. The integration of AKI and an elevation in plasma level of high sensitivity cardiac troponin T after PCI predicted more major cardiovascular events in acute coronary syndrome patients. Euro. Heart J. 2017;38(Suppl_1): 6486, doi.org/10.1093/eurheartj/ehx493.P6486.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are required to sign and submit the completed “Copyright transfer Form” upon acceptance of publication of the paper. This is determined by a publishing agreement between the author and International Archives of Biomedical and Clinical Research. These rights might include the right to publish, communicate and distribute online. Author(s) retain the copyright of their work. International Archives of Biomedical and Clinical Research supports the need for authors to share, disseminate and maximize the impact of their research.
